Congress 117 - HR 2366 - STOP Fentanyl Act of 2021

Sponsor

Cosponsors

Topics

American Samoa Cardiovascular and respiratory health Civil actions and liability Congressional oversight Corporate finance and management Correctional facilities and imprisonment Criminal investigation, prosecution, interrogation Criminal justice information and records Criminal procedure and sentencing Customs enforcement Drug safety, medical device, and laboratory regulation Drug therapy Drug trafficking and controlled substances Drug, alcohol, tobacco use Emergency medical services and trauma care Federal preemption Government information and archives Government studies and investigations Health Health care costs and insurance Health care coverage and access Health information and medical records Health programs administration and funding Health promotion and preventive care Health technology, devices, supplies HIV/AIDS Home and outpatient care Indian social and development programs Infectious and parasitic diseases Inflation and prices Internet and video services Internet, web applications, social media Law enforcement administration and funding Law enforcement officers Manufacturing Marketing and advertising Medical research Mental health Minority health Northern Mariana Islands Performance measurement Postal service Prescription drugs Research administration and funding Research and development Rural conditions and development Smuggling and trafficking State and local government operations Telephone and wireless communication Trade restrictions U.S. territories and protectorates

Full Text

View Full Bill Text

Votes

Summary

Support, Treatment, and Overdose Prevention of Fentanyl Act of 2021 or the STOP Fentanyl Act of 2021

This bill addresses data collection, treatment, harm reduction, and other issues related to substance misuse and addiction. It particularly focuses on opioids, fentanyl, and related substances.

Specifically, the bill expands surveillance of fentanyl and related substances. This includes establishing a pilot program to screen for contaminants in illicit drugs and a grant program to collect data on fentanyl-involved overdoses. The bill also specifies requirements concerning the collection and use of information about drugs seized by law enforcement.

Additionally, the bill establishes and modifies requirements to increase access to treatment and prevention services. For example, the Bureau of Prisons must make certain services, including medication-assisted treatments, available to individuals in its custody. The bill also

repeals a provision that requires dependence on opioids for at least one year before an individual may be admitted to certain treatment programs;
allows providers to prescribe medications to treat substance use disorders following a telehealth evaluation;
creates grant programs for treatment and harm reduction activities; and
addresses issues pertaining to opioid overdose reversal drugs.

Furthermore, the bill limits civil and criminal liability under specified laws for individuals who administer opioid overdose reversal drugs to an individual who reasonably appears to be experiencing an overdose, as well as for individuals who seek medical attention for themselves or on behalf of another for a drug overdose.

The bill also requires multiple reports, including a report by the Department of State on foreign sources of certain drugs.

Actions

Oct 19, 2021

Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Apr 13, 2021

Referred to the Subcommittee on Health.
Apr 5, 2021

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 5, 2021

Introduced in House

Amendments

Related Bills